ILA - Media coverage, page-61

Takeda's QDENGA® vaccine and Island Pharmaceuticals' ISLA-101 are both aimed at combating dengue fever, but they serve different purposes and are not direct competitors.

QDENGA® (Takeda):

• Type:Live-attenuated tetravalent vaccine.Takeda Pharmaceuticals: Global Homepage+1Takeda Pharmaceuticals: Global Homepage+1

• Purpose:Prevention of dengue infection.

• Target Population:Individuals aged 6 to 16 years in high-risk areas.Pharmaceutical Technology+2Reuters+2Takeda Pharmaceuticals: Global Homepage+2

• Administration:Two subcutaneous doses over three months.Reuters+3Takeda Pharmaceuticals: Global Homepage+3Clinical Trials Arena+3

• Efficacy:Demonstrated 80.2% efficacy against symptomatic dengue and 90.4% against hospitalization at 18 months post-vaccination.Takeda Pharmaceuticals: Global Homepage+1Takeda Pharmaceuticals: Global Homepage+1

• Regulatory Status:Approved in several countries, including the EU, Indonesia, Thailand, Argentina, and Brazil.Reuters

ISLA-101 (Island Pharmaceuticals):

• Type:Repurposed small-molecule antiviral drug.islandpharmaceuticals.com+5islandpharmaceuticals.com+5islandpharmaceuticals.com+5

• Purpose:Both prevention and treatment of dengue fever.Reuters

• Administration:Oral dosage.Pharmaceutical Technology+11Reuters+11islandpharmaceuticals.com+11

• Clinical Status:Completed Phase 2a/b PROTECT trial, showing a favorable safety profile and antiviral activity.

• Target Population:Potentially broader, including individuals already infected with dengue.

Comparison and Potential Synergy:

While both products aim to address dengue fever, their roles differ:

• Prevention vs. Treatment:QDENGA® is designed to prevent dengue infection, whereas ISLA-101 is being developed to treat existing infections and possibly prevent disease progression.

• Population Coverage:QDENGA® is approved for a specific age group in certain regions, while ISLA-101 could potentially be used across various age groups and geographies, pending regulatory approvals.

• Administration Method:QDENGA® requires injection, which may limit its use in some settings, whereas ISLA-101's oral administration could offer more flexibility.

Given these differences, ISLA-101 could complement existing vaccines like QDENGA® by providing a treatment option for those who contract dengue, including individuals not covered by vaccination programs.

Conclusion:

QDENGA® and ISLA-101 are not direct competitors but rather address different aspects of dengue fever management.QDENGA® focuses on prevention through vaccination, while ISLA-101 aims to provide therapeutic benefits to those infected.Their distinct roles suggest potential for complementary use in comprehensive dengue control strategies.

Sources